SpringWorks Therapeutics SWTX 深 沪
等待开盘 08-21 09:30:00 美东时间
46.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 46.99
- 总市值 35.41亿
- 52周最高 62.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 28.21
- 委 比 0.00%
- 总股本 7534.90万
- 历史最高 96.48
- 量 比 0
- 振 幅 0.00%
- 历史最低 13.60
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
Dr. Freda Lewis-Hall, a prominent psychiatrist and biopharmaceutical executive, has been appointed to Helus Pharma's Board of Directors and will also serve as Chair of the Scientific Advisory Committee. With over 40 years of experience, she will guide the company's clinical development strategy, regulatory engagement, and translational rigor across its novel serotonergic agonist portfolio. Helus Pharma is focused on developing innovative treatmen...
02-24 12:45
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics announced that the European Commission has granted marketing authorization for OGSIVEO® (nirogacestat) as the first and only therapy approved in the EU for the treatment of adults with progressing desmoid tumors requiring systemic treatment. The approval is based on the Phase 3 DeFi trial, which demonstrated significant improvements in progression-free survival (PFS), objective response rate (ORR), and patient-reported ou...
2025-08-18 13:10
